Stryker Corporation $SYK Shares Bought by Stonebridge Financial Group LLC

Stonebridge Financial Group LLC increased its position in Stryker Corporation (NYSE:SYK) by 16.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,134 shares of the medical technology company’s stock after acquiring an additional 2,251 shares during the period. Stonebridge Financial Group LLC’s holdings in Stryker were worth $5,079,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SYK. Godfrey Financial Associates Inc. acquired a new stake in Stryker in the fourth quarter valued at $26,000. Sankala Group LLC purchased a new stake in shares of Stryker in the 4th quarter worth about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new stake in Stryker in the 4th quarter valued at about $27,000. Finally, DJE Kapital AG purchased a new position in Stryker during the 4th quarter valued at about $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by insiders.

Stryker Stock Up 4.6%

Shares of NYSE SYK opened at $340.73 on Tuesday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The firm’s 50 day moving average price is $317.77 and its 200 day moving average price is $334.62. The firm has a market cap of $130.62 billion, a P/E ratio of 35.31, a price-to-earnings-growth ratio of 2.08 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the previous year, the company earned $3.13 EPS. Stryker’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 15.01 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th were given a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s payout ratio is currently 36.48%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. BMO Capital Markets started coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target on the stock. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a report on Friday. Royal Bank Of Canada dropped their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research report on Friday. Finally, BTIG Research reduced their price objective on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.